Kisqali

Kisqali. It is a prescription medication used in combination with other agents for the treatment of specific types of advanced breast cancer. Developed by the Swiss multinational Novartis, it belongs to a class of drugs known as cyclin-dependent kinase inhibitors. Its approval by regulatory bodies like the U.S. Food and Drug Administration and the European Medicines Agency marked a significant advancement in oncology.

Medical uses

This pharmaceutical is indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. It is also approved for use in combination with fulvestrant for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer as initial endocrine-based therapy or following disease progression on endocrine therapy. Clinical trials, such as the pivotal MONALEESA-7 and MONALEESA-3 studies, demonstrated significant improvement in progression-free survival compared to endocrine therapy alone. Its use is guided by specific diagnostic criteria and is not indicated for other cancer types like triple-negative breast cancer.

Adverse effects

Common adverse reactions include neutropenia, leukopenia, nausea, fatigue, diarrhea, alopecia, and elevated levels of alanine aminotransferase and aspartate aminotransferase. Serious side effects can involve severe neutropenia and associated febrile neutropenia, which require careful monitoring of complete blood count. Other significant risks include QT interval prolongation, which necessitates monitoring via electrocardiogram, and potential for hepatotoxicity. Management strategies often involve dose interruptions or reductions as outlined in prescribing information from health authorities like the FDA.

Pharmacology

As a selective inhibitor of cyclin-dependent kinase 4 and 6, it works by blocking the transition from the G1 phase to the S phase of the cell cycle, thereby inhibiting cellular proliferation in cancer cells. This mechanism is particularly effective in HR-positive breast cancer, where cancer cell growth is often driven by estrogen receptor signaling and CDK4/6 activity. The drug is administered orally and is metabolized primarily in the liver via the cytochrome P450 system, specifically CYP3A4. Concomitant use with strong CYP3A inhibitors or inducers is contraindicated due to significant drug interaction potential.

History

The development program was led by researchers at Novartis Institutes for BioMedical Research. Key clinical trials, including MONALEESA-2, were presented at major oncology conferences such as those held by the American Society of Clinical Oncology. It received its first global approval from the FDA in March 2017, based on data showing substantial improvement in progression-free survival. Subsequent approvals followed from the EMA and other regulatory agencies worldwide. Ongoing research includes investigations into its efficacy in other settings and combinations, contributing to the evolving landscape of breast cancer treatment.

Society and culture

The introduction of this therapy was a notable event within the pharmaceutical industry and patient advocacy communities, such as Breast Cancer Now. Its brand name has become widely recognized in discussions about modern cancer treatment. The cost and access to the medication have been subjects of debate within healthcare systems, involving entities like the National Institute for Health and Care Excellence in the United Kingdom. Patient assistance programs have been established by the manufacturer to support access. Its story is often cited alongside other CDK4/6 inhibitors like palbociclib and abemaciclib in narratives about innovation in targeted therapy.

Category:Antineoplastic drugs Category:Novartis brands Category:Cyclin-dependent kinase inhibitors